Rheumatoid Arthritis Pharmaceutical and Healthcare Analysis Information

Pune India - March 14, 2018 /MarketersMedia/ —

Summary
Rheumatoid Arthritis (RA) is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the RA space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/3054186-rheumatoid-arthritis-ra-dynamic-market-forecast-to-2025

Scope
Key events covered in the Dynamic Market Forecast include -
- Regulatory filings
- Approval decisions
- Pricing changes
- Patent litigation
- Clinical trial data announcements
- Clinical trial failures
- Clinical trial timeline updates

Components of the slide deck include -
- Timeline of market-impacting events
- Key clinical trial landscape updates
- Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
- Overview of updates to the forecast model based on anticipated future impact of events
- Forward-looking events calendar listing expected key updates to the RA competitive space through June 2018

Reasons to buy
- Recent Regulatory Events
- Recent Commercial Events
- Recent Clinical Events
- Market Dynamics Shifts Towards Biosimilars in the RA Setting
- Discontinuation of J&J’s Sirukumab for RA Creates Opportunity for Other IL-6 Inhibitors
- Increased Competition Among the Oral JAK Inhibitors in the RA Setting

Table of Content: Key Points
1. Dynamic Market Forecast Overview 5
1.1 Related Reports 6
1.2 Upcoming Related Reports 7
2. Executive Summary 8
2.1 Key Updates to RA Market Dynamics 9
2.1 Key Events in Update 10-12
2.2 Clinical Trial Landscape Updates 13
2.3 Pipeline Landscape Updates 14
2.4 Market Insight on Key Events 15
3. Event 1: Market Dynamics Shift Towards Biosimilars 16
3.1 Key Updates to Biosimilar Market Dynamics 17
3.2 Enbrel Biosimilars 18
3.3 Humira Biosimilars 19
3.4 Remicade Biosimilars 20
3.5 Rituxan Biosimilars 21
3.6 What Do Physicians Think? 22
3.7 Summary/Trends 23
3.8 Sources 24
4. Event 2: Discontinuation of Sirukumab Creates Opportunity for Other IL-6 Inhibitors 25
4.1 Key Updates to the Anti-IL-6 Market Dynamics 26
4.2 J&J, sirukumab 27
4.3 Regeneron/Sanofi, Kevzara (sarilumab) 28
4.4 What Do Physicians Think? 29
4.5 Summary/Trends 30
4.6 Sources 31
5. Event 3: Competition Among the Oral JAK Inhibitors 32
5.1 Key Updates to the JAK Inhibitor Market Dynamics 33
5.2 Eli Lilly, Olumiant (baricitinib) 34-35
5.3 AbbVie, upadacitinib 36
5.4 What Do Physicians Think? 37
5.5 Summary/Trends 38
5.6 Sources 39
6. Events Calendar 40
6.1 Key Events Expected to Occur H1 2018 41
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/3054186-rheumatoid-arthritis-ra-dynamic-market-forecast-to-2025

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +1-646-845-9349
Website: http://www.wiseguyreports.com

Release ID: 314312